The Effects of Nobiletin and Devil’s Claw in Hela Cervical Cancer Cell Lines
Ozlem Ozgur Gursoy1*,Hulusi Goktug Gurer1, Ceren Yildiz Eren1,
Canan Vejselova Sezer2
1Eskisehir Acibadem Hospital, Obstetrics and Gynecology Clinic, Eskisehir, Turkey
2Eskişehir Technical University, Faculty of Science, Department of Biology Eskisehir, Turkey.
*Corresponding Author: Ozlem Ozgur Gursoy, Eskisehir Acibadem Hospital, Obstetrics and Gynecology Clinic, Eskisehir, Turkey.
June 24, 2022; Published: June 28, 2022
Cervical cancer is the fourth most common type of cancer diagnosed in women. Devil's Claw (Harpagophytum procumbens) is a traditional medicine that has been used for a long time. Nobiletin (3′,4′,5,6,7,8-hexamethoxyflavone) is an important component of polymethoxylated flavones found in citrus peels.
HeLa cells were cultured in EMEM medium. HeLa cells were seeded in 96 well plates. After the incubation, plates were read at 570 nm on ELISA reader. Annexin-V technique, based on detection of translocated phosphatidylserine to the outer side of cellular membrane, was used to test the apoptosis promoting ability of test agents on HeLa cells. The Caspase 3/7 activation abilities of test agents on HeLa cells were analysed with caspase 3/7 detection technique.
Devil’s claw, nobiletin and the combination of these 2 agents were found to be cytotoxic on human cervix adenocarcinoma cells, HeLa. The cytotoxic effects of all agents were in dose and time dependent. The highest growth inhibiton was detected at the applied highest dose. IC50 values for 24 hours were found to be 51.12, 49.03 and 39.2 μg/mL, respectively. This values for 48 hours of application were 43.23, 45.12 and 30.65 μg/mL for Devil’s claw, nobiletin and the combination.
Today, combined therapy has come to the fore in the treatment of cancer patients. Nobiletin and devil's claw may be candidates for inclusion in treatment protocols as well as being used alone.
Keywords: HeLa Cells; Devil's Claw; Nobiletin; Cell Viability; Annexin-V
- Zhang S., et al. “Cervical cancer: Epidemiology, risk factors and screening”. Chinese Journal of Cancer Research 6 (2020): 720-728.
- Bray F., et al. “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries”. CA Cancer Journal of Clinics6 (2018): 394-424.
- Prabhu M and Eckert LO. “Development of World Health Organization (WHO) recommendations for appropriate clinical trial endpoints for next-generation Human Papillomavirus (HPV) vaccines”. Papillomavirus Research (Amsterdam, Netherlands) 2 (2016): 185-189.
- Mirabelli P., et al. “Cancer Cell Lines Are Useful Model Systems for Medical Research”. Cancers (Basel)8 (2019): 1-18.
- Hynds RE., et al. “The secret lives of cancer cell lines”. Disease Models and Mechanisms 11 (2018): 1-5.
- Hansen MB., et al. “Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill”. Journal of Immunological Methods 2 (1989): 203-210.
- Tada H., et al. “An improved colorimetric assay for interleukin 2”. Journal of Immunological Methods 2 (1986): 157-165.
- Crowley LC., et al. “Quantitation of Apoptosis and Necrosis by Annexin V Binding, Propidium Iodide Uptake, and Flow Cytometry”. Cold Spring Harbor Protocols 11 (2016).
- Brendler T. “From Bush Medicine to Modern Phytopharmaceutical: A Bibliographic Review of Devil’s Claw (Harpagophytum)”. Pharmaceuticals (Basel) 14.8 (2021): 726.
- Kanda K., et al. “Nobiletin suppresses adipocyte differentiation of 3T3-L1 cells by an insulin and IBMX mixture induction”. Biochimica et Biophysica Acta 4 (2012): 461-468.
- Lee Y-C., et al. “Nobiletin, a citrus flavonoid, suppresses invasion and migration involving FAK/PI3K/Akt and small GTPase signals in human gastric adenocarcinoma AGS cells”. Molecular and Cellular Biochemistry 1-2 (2011): 103-115.
- Cui Y., et al. “Anti-neuroinflammatory activity of nobiletin on suppression of microglial activation”. Biological and Pharmaceutical Bulletin 11 (2010): 1814-1821.
- Mulvihill EE., et al. “Nobiletin attenuates VLDL overproduction, dyslipidemia, and atherosclerosis in mice with diet-induced insulin resistance”. Diabetes 5 (2011): 1446-1457.
- Moon JY., et al. “Nobiletin induces apoptosis and potentiates the effects of the anticancer drug 5-fluorouracil in p53-mutated SNU-16 human gastric cancer cells”. Nutrition Cancer2 (2013): 286-295.
- Kamioka H., et al. “Moesin-Mediated P-Glycoprotein Activation During Snail-Induced Epithelial-Mesenchymal Transition in Lung Cancer Cells”. Journal of Pharmaceutical Sciences 7 (2020): 2302-2308.
- Dong J., et al. “Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update”. Drug Resistance Updates 49 (2020): 100681.
- Wesołowska O., et al. “Multidrug resistance reversal and apoptosis induction in human colon cancer cells by some flavonoids present in citrus plants”. Journal of Natural Products 11 (2012): 1896-1902.
- Feng S., et al. “Nobiletin and its derivatives overcome multidrug resistance (MDR) in cancer: total synthesis and discovery of potent MDR reversal agents”. Acta Pharmaceutica Sinica B 2 (2020): 327-343.
- Cole SP., et al. “Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line”. Science5088 (1992): 1650-1654.
- Moon JY., et al. “Nobiletin Enhances Chemosensitivity to Adriamycin through Modulation of the Akt/GSK3β/β−Catenin/MYCN/MRP1 Signaling Pathway in A549 Human Non-Small-Cell Lung Cancer Cells”. Nutrients 12 (2018).
- Hong T., et al. “miR-7 Reverses Breast Cancer Resistance To Chemotherapy By Targeting MRP1 And BCL2”. OncoTargets and Therapy 12 (2019): 11097-11105.
- Chrubasik S. “Addendum to the ESCOP monograph on Harpagophytum procumbens”. Phytomedicine: international Journal of Phytotherapy and Phytopharmacology. Germany (2004): 691-5; author reply 696.
- Peruru R., et al. “Devil’s claw (Harpagophytum procumbens) ameliorates the neurobehavioral changes and neurotoxicity in female rats exposed to arsenic”. Heliyon 5 (2020): e03921-e03921.
- Schaffer LF., et al. “Harpagophytum procumbens prevents oxidative stress and loss of cell viability in vitro”. Neurochemistry Research11 (2013): 2256-2267.
- Wilson KS. “Regression of follicular lymphoma with Devil’s Claw: coincidence or causation?” Current Oncology4 (2009): 67-70.